Characterization and Prognosis of Secondary Acute Myeloid Leukemia in an Asian Population: AML With Antecedent Hematological Disease Confers Worst Outcomes, Irrespective of Cytogenetic Risk | Anticancer Research
Effect of therapy-related acute myeloid leukemia on the outcome of patients with acute myeloid leukemia
Challenging the concept of de novo acute myeloid leukemia: Environmental and occupational leukemogens hiding in our midst - ScienceDirect
Key Topic Videos | MYLOTARG®▽(gemtuzumab ozogamicin) | PfizerPro UK
Secondary acute myeloid leukemia
How do doctors tell de novo acute myeloid leukemia (de novo AML), AML-MRC, and tAML apart? - YouTube
Common mutations in de novo and secondary AML. A number of clonal blood... | Download Scientific Diagram
Redefining prognostication of de novo cytogenetically normal acute myeloid leukemia in young adults | Blood Cancer Journal
Characterization and Prognosis of Secondary Acute Myeloid Leukemia in an Asian Population: AML With Antecedent Hematological Disease Confers Worst Outcomes, Irrespective of Cytogenetic Risk | Anticancer Research
High efficacy of Azacitidine plus HAG in acute myeloid leukemia: an open-label, single-arm, multi-center, phase 2 study | Blood Cancer Journal
Association of mutations with morphological dysplasia in de novo acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities | Haematologica
Recurrent mutation groups in de novo AML. Genes recurrently mutated in... | Download Scientific Diagram
AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics | Leukemia
Survival of de novo acute myeloid leukemia at MD Anderson (1970-2017)... | Download Scientific Diagram
Secondary acute myeloid leukemia
Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1 - Modern Pathology
Trends in acute myeloid leukaemia in Western Australia over time: Improved outcomes with contemporary management | Tasman Medical Journal
Secondary vs de novo acute myeloid leukemia
JCM | Free Full-Text | Revealing the Mysteries of Acute Myeloid Leukemia: From Quantitative PCR through Next-Generation Sequencing and Systemic Metabolomic Profiling
Decitabine shows comparable OS to standard induction chemotherapy and better safety in patients with AML
Overall survival time in de novo AML and in t-AML. t-AML,... | Download Scientific Diagram
IJMS | Free Full-Text | Application of High Throughput Technologies in the Development of Acute Myeloid Leukemia Therapy: Challenges and Progress
